98%
921
2 minutes
20
Background: Advances in surgical technique and prosthesis design have expanded the non-neoplastic indications for proximal femoral replacement (PFR) to include fracture nonunion, periprosthetic fracture, and severe bone loss in the setting of revision total hip arthroplasty (THA). The purpose of this study is to assess outcomes of PFRs used for nononcologic indications.
Methods: A single-institution, retrospective, cohort survey study was conducted between August 2015-February 2020 of consecutive patients undergoing PFR for nononcologic indications in revision THA. Patient demographics, surgical variables, complications, and revision procedures were collected. Patient satisfaction and Oxford Hip scores were assessed via a telephone questionnaire. Implant survivorship was estimated using the Kaplan-Meier method.
Results: In total, 24 patients (27 PFRs) were available for analysis with an average age of 69.3 ± 12.9 years (range: 37-90). The average number of operations prior to PFR implantation was 3.1 ± 2.1 (range: 0-7). At a mean follow-up of 2.4 years (range: 0.5-5.1), the mean Oxford Hip Score was 31.7 ± 10.2, and mean patient satisfaction was 4.9/5. Six patients (20.7%) experienced a postoperative complication, with dislocation occurring in three patients (10.3%). None of the patients with dual mobility articulations (n = 4) had dislocation. Three-year survivorship was 85.2% (95% CI 71.8%-98.6%) with all-cause reoperations as the endpoint and 100% (95% CI 100.0%-100.0%) with revision for aseptic loosening as the endpoint.
Conclusion: The current study demonstrates excellent short-term survivorship, satisfactory patient-reported outcomes, and high patient satisfaction following PFR for nononcologic indications during revision THA utilizing modern techniques. The most common mode of failure was dislocation requiring reoperation with revision to constrained acetabular components.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arth.2022.02.057 | DOI Listing |
SICOT J
August 2025
First Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, Rimini Street, Chaidari 124 62, Athens, Greece.
Background: Proximal femoral megaprosthetic reconstruction is a well-established solution for extensive bone loss in the hip region. Despite its utility in limb salvage, it carries notable complication rates, reported between 30% and 40%, along with increased morbidity and mortality. This study evaluated implant and patient survival, failure modes, and associated risk factors.
View Article and Find Full Text PDFJ Robot Surg
August 2025
Department of Obstetrics, Gynaecology, and Gynaecologic Oncology, Regional Polyclinical Hospital, Grudziadz, Poland.
Surgical treatment in patients over the age of 70 presents distinct challenges due to a combination of their overall health status and age-related physiological changes. Hysterectomy remains one of the most frequently performed surgeries in women. Advancements in surgical techniques, especially the introduction of minimally invasive surgery (MIS), which facilitated the development of laparoscopic and robotic-assisted hysterectomy, have transformed the standard of care.
View Article and Find Full Text PDFSurg Oncol
August 2025
Department of Orthopedic Surgery, Stanford University 450 Broadway Street Pavilion C, MC 6342 Redwood City, CA 94063, USA. Electronic address:
Background: Non-oncologic resection of soft tissue sarcomas (STS) continue to be a common referral to multidisciplinary sarcoma centers. While previous literature has reported tumor characteristics and outcomes related to non-oncologic resections, little is known regarding the surgical specialties most likely to excise such a mass and the non-oncological manner in which they do so. Such information can facilitate preventative strategies.
View Article and Find Full Text PDFJ Arthroplasty
July 2025
Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Background: Proximal femoral replacement (PFR) is a salvage procedure in revision total hip arthroplasty for extensive femoral bone loss. This study aimed to evaluate implant survivorship, complications, patient mortality, and clinical outcomes of PFR for non-oncologic indications at mid-term follow-up (five years).
Methods: We reviewed 61 PFRs for nononcologic indications performed between 2000 and 2022 at a single academic institution.
J Allergy Clin Immunol
September 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address:
As an essential component of the FcεRI pathway, Bruton tyrosine kinase (BTK) has become a target for treating allergic diseases. Several proof-of-concept studies using early-generation compounds such as ibrutinib and acalabrutinib demonstrated the ability of short courses of BTK inhibitors (BTKis) to reduce skin test responses to allergens, suppress basophil activation responses, and even completely prevent reactivity to allergenic food ingestion in humans. While early-generation BTKis do not have acceptable adverse effect profiles for chronic administration for nononcologic indications, newer compounds in development have higher selectivity for BTK and fewer adverse effects.
View Article and Find Full Text PDF